Patient Guide: Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 37 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT04097470
Status: ACTIVE_NOT_RECRUITING
Condition: AML/MDS
Phase: PHASE2

Where You Can Participate

This study is available at 37 locations across the country.

Top locations include:
  • • Antwerpen,
  • • Haine-Saint-Paul,
  • • Roeselare,
  • • And 34 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients - Join Clinical Trial NCTNCT04097470

How to Join This Clinical Trial - NCTNCT04097470

Learn how to participate in this PHASE2 trial studying an investigational therapy for AML/MDS. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with AML/MDS. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
AML/MDS
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT04097470 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 37 locations. Find a study site near you:

Clinical Research Site

Antwerpen, - Belgium

Status: Contact for availability

Clinical Research Site

Haine-Saint-Paul, - Belgium

Status: Contact for availability

Clinical Research Site

Roeselare, - Belgium

Status: Contact for availability

Clinical Research Site

Magdeburg, - Germany

Status: Contact for availability

Clinical Research Site

Amersfoort, - Netherlands

Status: Contact for availability

Clinical Research Site

Amsterdam, - Netherlands

Status: Contact for availability

Clinical Research Site

Amsterdam, - Netherlands

Status: Contact for availability

Clinical Research Site

Arnhem, - Netherlands

Status: Contact for availability

Clinical Research Site

Breda, - Netherlands

Status: Contact for availability

Clinical Research Site

Delft, - Netherlands

Status: Contact for availability

And 27 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for AML/MDS:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships